Demand for Pulmonary Arterial Hypertension Treatment in USA

Future Market Insights

Key Insight

The demand for pulmonary arterial hypertension treatment in USA is projected to grow from USD 784.8 million in 2026 to USD 973.1 million by 2036, at a CAGR of 2.2%. Endothelin receptor antagonists (ERA) will dominate with a 38.0% market share, while hospital pharmacies will lead the distribution channel segment with a 44.0% share.

December 24, 2025

Anurag Sharma

250 Pages

Cite this Report

Demand for Pulmonary Arterial Hypertension Treatment in USA

https://www.futuremarketinsights.com/reports/united-states-pulmonary-arterial-hypertension-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Actelion (Janssen)
Bayer Healthcare LLC
Merck KGaA
The Vanguard Group
United Therapeutics Corporation

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Demand for Pulmonary Arterial Hypertension Treatment in USA

Key Players

Similar Industry Reports